重组人促红细胞生成素治疗非肾性贫血。

Recombinant human erythropoietin in the treatment of nonrenal anemia.

作者信息

Heuser Michael, Ganser Arnold

机构信息

Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Carl-Neuberg-Str 1, 30625, Hannover, Germany.

出版信息

Ann Hematol. 2006 Feb;85(2):69-78. doi: 10.1007/s00277-005-1086-5. Epub 2005 Aug 3.

DOI:10.1007/s00277-005-1086-5

PMID:16078035

Abstract

Recombinant human erythropoietins (rhEPO) reliably increase hemoglobin levels in cancer patients experiencing chemotherapy-associated anemia. However, in patients with "anemia of cancer" not being treated with chemotherapy, rhEPO appears less effective. Recently, two studies have been broadly discussed which have raised concern on the concomitant use of erythropoietin and chemo- or radiation therapy in cancer patients. In addition, use of rhEPO is generally not considered cost-effective. Thus, the application of rhEPO should be limited to indications with proven clinical benefit. This review will provide an overview of the state of the art use of rhEPO in anemic patients and will discuss future developments.

摘要

重组人促红细胞生成素（rhEPO）能可靠地提高接受化疗相关贫血治疗的癌症患者的血红蛋白水平。然而，在未接受化疗的“癌症贫血”患者中，rhEPO的效果似乎较差。最近，有两项研究受到广泛讨论，这两项研究引发了人们对癌症患者同时使用促红细胞生成素与化疗或放疗的担忧。此外，rhEPO的使用通常不被认为具有成本效益。因此，rhEPO的应用应限于已证实具有临床益处的适应症。本综述将概述rhEPO在贫血患者中的最新应用情况，并讨论未来的发展。